Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amgen
Biotech
TScan’s strategy unaffected by Amgen scrapping $500M+ collab
“There are no planned changes to our wholly owned programs as a result of the Amgen collaboration being terminated,” TScan told Fierce.
Darren Incorvaia
Aug 19, 2026 5:31pm
Amgen lays groundwork for new R&D center in Hyderabad
Aug 11, 2026 2:05pm
Amgen drops ph. 1 obesity drug, upping pressure on MariTide
Aug 4, 2026 4:01pm
Amgen sheds around 40 staffers as struggles mount
Jul 24, 2026 4:45pm
Roche orchestrates phase 3 lung cancer win over Amgen and BMS
Jul 2, 2026 8:30am
Fierce Pharma
FDA snubs Sobi’s gout drug over manufacturing issues
Jun 29, 2026 11:04am
